Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Adverse events: clinically relevant non‐major bleeding / heparin‐induced thrombocytopenia ‐ not reported · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
HIT in people undergoing major surgical procedures · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT in people undergoing major surgical procedures (low certainty).
1 finding from 1 review
Intervention not reported
HIT complicated by venous thromboembolism · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower HIT complicated by venous thromboembolism (low certainty).
1 finding from 1 review
Intervention not reported
All VTE · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT (sensitivity analysis unpublished) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (sensitivity analysis unpublished) (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (moderate certainty).
1 finding from 1 review
Intervention not reported
Proximal DVT · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower proximal DVT (moderate certainty).
1 finding from 1 review
Intervention not reported
Symptomatic VTE · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in symptomatic VTE (moderate certainty).
1 finding from 1 review
Intervention not reported
Bleeding complications · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in bleeding complications (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · patients undergoing abdominal or pelvic surgery
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All DVT (subgroup analysis open only) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all DVT (subgroup analysis open only) (moderate certainty).
1 finding from 1 review
Intervention not reported
All VTE (sensitivity analysis unpublished) · patients undergoing abdominal or pelvic surgery
The intervention probably leads to lower all VTE (sensitivity analysis unpublished) (moderate certainty).
1 finding from 1 review